Ribonucleoprotein (RNP) 抗体
适用: 人
IHC (fro), FACS, IHC (p)
宿主: 小鼠
Monoclonal
58-15
unconjugated
-
- 抗原
- Ribonucleoprotein (RNP)
- 适用
- 人
- 宿主
- 小鼠
- 克隆类型
- 单克隆
- 应用范围
- Immunohistochemistry (Frozen Sections) (IHC (fro)), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- 交叉反应 （详细）
- Species reactivity (tested):Human.
- 纯化方法
- Purified
- 免疫原
- Isolated nuclei. Splenocytes were fused with mouse myeloma NS-1 cells.
- 克隆位点
- 58-15
- 亚型
- IgM
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 限制
- 仅限研究用
-
- 浓度
- 0.1 mg/mL
- 缓冲液
- PBS, 0.05 % Sodium Azide
- 储存液
- Sodium azide
- 注意事项
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 注意事项
- Avoid repeated freezing and thawing.
- 储存条件
- 4 °C/-20 °C
- 储存方法
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
- 抗原
- Ribonucleoprotein (RNP)
- 背景
- Anti-nuclear antibodies remain prevalent in a large group of autoimmune disorders. The accumulation of anti-nuclear antibodies is characteristic of lupus erythematosus, as well as various other auto-immune diseases such as Sjögren's syndrome, autoimmune hepatitis, dermatomyositis, rheumatoid arthritis, and scleroderma. Ribonucleoproteins (RNP) represent a 20-80nm electron dense nuclear structure, with highest labeling densities found in nuclear ribonucleoprotein (nRNP) particles. One of the main components of the nucleolus, RNPs are comprised of ribonucleic acid (RNA) and protein together, representing an RNA binding motif in an RNA binding protein. Aromatic amino acid residues occupying this RNP motif, create stacking interactions with RNA. Lysine residues expressed exclusively in the helical portion of RNA binding proteins stabilizes relationships with nucleic acids. The ability to quantitate and identify dividing cells facilitates immunopathologic studies on tissues from which prognostic information can be derived for disease states such as cancer.
-
You are here:
